Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast
LGND analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.73 / 5 from 11 analysts
- Price target
- $344.25 average of analyst targets
- Upside to target
- +16.5% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $1.42
- 52-week range
- $181.65 – $322.61
LGND analyst ratings
11 analystsNumber of analysts at each rating.
LGND price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LGND earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.31 | $1.93 | $2.49 | $3.09 | −25.3% | 10 |
| Current fiscal year (2026) | $9.31 | $9.09 | $9.50 | $8.13 | +14.5% | 10 |
| Next fiscal year (2027) | $11.95 | $10.51 | $13.46 | $9.31 | +28.4% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LGND revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $78.0M | $65.5M | $91.7M | −32.4% | 11 |
| Current fiscal year (2026) | $289.6M | $277.8M | $306.5M | +8.0% | 11 |
| Next fiscal year (2027) | $381.5M | $351.4M | $408.4M | +31.7% | 10 |
LGND EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LGND revenue: reported and forecast
LGND EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.51 | $2.56 | $2.30 | $2.30 | $2.31 | −8.0% | 0 up · 1 down |
| Current fiscal year (2026) | $9.10 | $9.18 | $9.32 | $9.32 | $9.31 | +2.2% | 1 up · 1 down |
| Next fiscal year (2027) | $11.32 | $11.83 | $11.93 | $11.93 | $11.95 | +5.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LGND earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LGND beat in 11 of 12.
What analysts expect from LGND
11 analysts cover Ligand Pharmaceuticals; their consensus rating is strong buy (4.73 on a 1–5 scale, where 5 is a strong buy). The average price target is $344.25, 16.5% above the latest close of $295.54. Analysts expect earnings of $9.31 per share for 2026, +14.5% from a year earlier. For 2027 the average estimate is $11.95 per share on revenue of $381.5 million. Ligand Pharmaceuticals beat the EPS estimate in 11 of the last 12 quarters.
Related: LGND income statement, LGND key metrics, LGND chart. See the LGND stock overview for the latest quote and news.
LGND forecast FAQ
What is Ligand Pharmaceuticals's price target?
The average analyst price target for Ligand Pharmaceuticals is $344.25, 16.5% above the latest close of $295.54.
Is Ligand Pharmaceuticals a buy, hold or sell?
Of 11 analysts covering Ligand Pharmaceuticals, 8 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ligand Pharmaceuticals's EPS forecast?
Analysts forecast $9.31 per share for 2026 (range $9.09 to $9.50); for 2027 the estimate is $11.95.
What is Ligand Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $289.6 million, growth of 8.0%; for 2027 it is $381.5 million.
When does Ligand Pharmaceuticals report earnings?
Ligand Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $1.42.
Does Ligand Pharmaceuticals usually beat earnings estimates?
Ligand Pharmaceuticals reported EPS at or above the analyst estimate in 11 of the last 12 quarters.